Proceedings of the 2017 International Conference of Precision Health and Precision Nutrition

摘要

One fundamental principle of biology is interaction, understandingof which forms the basis for the development of novel therapeuticand preventive strategies with proven clinical efficacy (Phase III)and population effectiveness (Phase IV and implementation). Theexisting research and implementation processes for both drugtherapy and new diagnostic tools are very fragmented and grosslyinsufficient. First, the drug development process takes too long (10-15 years/drug) and cost too much (~$1 billion/drug) with high failurerates (~80%) even for targets and compounds that survivethrough Phases II development. Second, the lack of assessment forinteractions among genetic factors and therapeutic agents in almostall human studies may be a rate-limiting step for success (orlead to post-marketing failure due to as yet unknown off-targetdetrimental effect). Third, current structure does not encouragebasic scientists to work closely with clinical and population scientists.Last and most importantly, insufficient measurement of covariatesoften precludes from confidently predicting intermediate orlong-term effects of various agents.